Patients confirmed to have EGFR p.T790M PGVs appear to have roughly a 23% increased risk of LC, and screening for LC might be considered in these patients and for other cancers if proven to be EGFR-associated. This evidence concerns the gene EGFR and laryngotracheoesophageal cleft.